| Medical and Health Sciences | Lifetime | 200 | SE 4 | 99.99 |
| Medical Physiology | Lifetime | 64 | SE 3 | 99.90 |
| Psychiatry and Mental health | Lifetime | 30 | SE 3 | 99.91 |
| Clinical Pharmacology | Lifetime | 118 | SE 4 | 99.50 |
| General Health Professions | Lifetime | 482 | SE 9 | 99.45 |
| Neuroscience of Neurology | Lifetime | 93 | SE 3 | 99.24 |
| Cellular and Molecular Neuroscience | Lifetime | 385 | SE 18 | 98.61 |
| Clinical Neurology | Lifetime | 501 | SE 18 | 97.80 |
| Health | Lifetime | 362 | SE 5 | 97.73 |
| Geriatrics and Gerontology | Lifetime | 296 | SE 7 | 92.64 |
| Periodontics | Lifetime | 704 | SE 33 | 79.48 |
| Biochemistry | Lifetime | 944 | SE 23 | 76.73 |
| Medical Physiology | 2021-2025 | 289 | SE 11 | 96.08 |
| Psychiatry and Mental health | 2021-2025 | 345 | SE 19 | 91.14 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 2 | SE 1 | 99.92 |
| Cholinesterase and Neurodegenerative Diseases | Lifetime | 4 | SE 1 | 99.92 |
| Dementia and Cognitive Impairment Research | Lifetime | 11 | SE 3 | 99.96 |
| Aging, Elder Care, and Social Issues | Lifetime | 18 | SE 2 | 98.79 |
| Alzheimer's disease research and treatments | Lifetime | 31 | SE 3 | 99.92 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 94 | SE 2 | 99.62 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 39 | SE 4 | 99.64 |
| Health disparities and outcomes | Lifetime | 158 | SE 4 | 99.16 |
| Neuroscience and Neuropharmacology Research | Lifetime | 378 | SE 14 | 99.47 |
| Geriatric Care and Nursing Homes | Lifetime | 92 | SE 2 | 99.07 |
| Frailty in Older Adults | Lifetime | 102 | SE 3 | 98.92 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 272 | SE 9 | 98.96 |
| Computational Drug Discovery Methods | Lifetime | 332 | SE 8 | 98.32 |
| Diet and metabolism studies | Lifetime | 903 | SE 38 | 98.45 |
| Nicotinic Acetylcholine Receptors Study | Lifetime | 185 | SE 4 | 98.12 |
| Tryptophan and brain disorders | Lifetime | 374 | SE 5 | 98.11 |
| Blood Pressure and Hypertension Studies | Lifetime | 544 | SE 17 | 98.45 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 537 | SE 13 | 98.27 |
| Chronic Disease Management Strategies | Lifetime | 693 | SE 14 | 96.18 |
| Nuclear Receptors and Signaling | Lifetime | 338 | SE 9 | 95.37 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 854 | SE 25 | 95.04 |
| Aging and Gerontology Research | Lifetime | 279 | SE 5 | 95.48 |
| Memory and Neural Mechanisms | Lifetime | 940 | SE 10 | 95.75 |
| Health, Environment, Cognitive Aging | Lifetime | 473 | SE 16 | 94.16 |
| Intergenerational Family Dynamics and Caregiving | Lifetime | 544 | SE 7 | 94.57 |
| Health and Well-being Studies | Lifetime | 702 | SE 6 | 92.87 |
| Diagnosis and treatment of tuberculosis | Lifetime | 748 | SE 10 | 92.08 |
| Cerebrovascular and genetic disorders | Lifetime | 249 | SE 13 | 91.04 |
| 14-3-3 protein interactions | Lifetime | 373 | SE 3 | 87.28 |
| Phosphodiesterase function and regulation | Lifetime | 480 | SE 6 | 88.25 |
| Prion Diseases and Protein Misfolding | Lifetime | 926 | SE 19 | 89.37 |
| Ginkgo biloba and Cashew Applications | Lifetime | 728 | SE 5 | 79.41 |
| Alzheimer's disease research and treatments | 2021-2025 | 342 | SE 30 | 96.35 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 387 | SE 37 | 96.64 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 839 | SE 10 | 74.19 |
| Heat shock proteins research | 2021-2025 | 401 | SE 12 | 66.99 |
